Migraine

Chronic Migraines And Cannabis: How One Mom Found Relief After A Lifetime Of Pain

AbbVie's Migraine Treatment Drug Touts Encouraging Data In Preventive Treatment Setting

Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints

AbbVie's Migraine Treatment Drug Touts Encouraging Data In Preventive Treatment Setting

Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints

ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine

Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial

ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine

Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial

FDA Clears Tonix Pharma's Human Trial With Intranasal Oxytocin For Migraine

Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M

Migraine Recent News

Cowen Sees 100% Upside For This Medical Device Firm

Cowen has raised Impel NeuroPharma Inc's (NASDAQ: IMPL) price target to $55 from $35, with an Outperform rating, after the FDA approved Trudhesa for the acute treatment of migraine. The analyst sees more than 100% upside for the stock.

FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock Jumps

Jim Cramer Says People Need To Know About Biohaven

Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) announced Wednesday that it has preliminary net revenue of approximately $93 million for its NURTEC ODT product in the second quarter of 2021.

Zosano Stock Surges After New Study Shows Qtrypta's Potential As Long-Term Treatment Option For Migraine

ElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For Migraine

The Street May Be Underappreciating Alder Biopharma's Phase 3 Data

Piper Jaffray Defends Alder Despite Stock Slump, Looks To What's Next In Migraine Management

Alder Biopharmaceuticals' New Drug Promises Migraine Relief, Stock Rally